Fig. 4 | Signal Transduction and Targeted Therapy

Fig. 4

From: Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study

Fig. 4

Total pathological complete response (tpCR) rates in HER2-positive breast cancer patients, stratified by tumour mutation burden (TMB) levels, RTK-RAS pathway mutation status, and pyrotinib treatment. The tpCR and non-tpCR rates were calculated for patients who completed six cycles of neoadjuvant treatment with TCbH plus pyrotinib in cohort C (a) and those who received TCbH alone (no pyrotinib) in cohorts A and B (b). Stratification was based on the combined status of TMB levels (high or low) and RTK-RAS pathway mutations (wild-type or mutant). P values for each comparison are presented

Back to article page